Evidence map›Paper›PMID 27186126›Full record

ReviewJournal of experimental pharmacology2012

The therapeutic potential of RORγ modulators in the treatment of human disease.

Mi Ra Chang, Devrishi Goswami, Becky A Mercer, Patrick R Griffin

Open access · goldAbstract readReview
In one paragraph

Review in Journal of experimental pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mi Ra ChangDepartment of Molecular Therapeutics, Scripps Florida, The Scripps Research Institute, Jupiter, FL, USA.
Devrishi GoswamiDepartment of Molecular Therapeutics, Scripps Florida, The Scripps Research Institute, Jupiter, FL, USA.
Becky A MercerTranslational Research Institute, Scripps Florida, The Scripps Research Institute, Jupiter, FL, USA.
Patrick R GriffinDepartment of Molecular Therapeutics, Scripps Florida, The Scripps Research Institute, Jupiter, FL, USA; Translational Research Institute, Scripps Florida, The Scripps Research Institute, Jupiter, FL, USA.
Scripps Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear receptors (NR) are ligand-regulated transcription factors that bind DNA in proximity to their target genes and exert their effects as a result of binding by small molecule ligands such as sterols, lipids, fatty acids, retinoids, and steroid hormones. The retinoic acid receptor-related orphan receptors or RORs (NR1F1-NR1F3) are nuclear receptors that regulate multiple cellular processes, including metabolism, cellular differentiation, and apoptosis, in a range of tissues and organs. These receptors bind as monomers to ROR response elements commonly called ROREs present in promoter regions of target genes and tether chromatin remodeling enzymes, facilitating recruitment of transcription machinery. Several recent reports have highlighted the potential role for RORs in human disease, and more importantly, studies have demonstrated that these receptors can be modulated by exogenous synthetic ligands, paving the way for development of novel therapeutics. Here we review the current status of synthetic ligand development as well as the structural aspects governing modulation of ROR signaling pathways as they relate to metabolic diseases and autoimmune disorders.

Indexed as

autoimmune disorderinverse agonistsligand-binding domain (LBD)metabolic disordernuclear receptor (NR) modulatorretinoic acid receptor-related orphan receptors (ROR)synthetic ligand

Identifiers

PMID27186126
PMCPMC4863310
OpenAlexW2029115856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.